A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Avadomide (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 23 May 2017 Planned End Date changed from 1 Feb 2021 to 23 Jun 2020.
- 23 May 2017 Planned primary completion date changed from 1 Feb 2021 to 23 Jun 2020.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.